Literature DB >> 19718471

Venous thromboembolic events in hospitalised medical patients.

Gregory Piazza1, John Fanikos, Maksim Zayaruzny, Samuel Z Goldhaber.   

Abstract

The number of acutely ill hospitalised medical patients at risk for acute venous thromboembolism (VTE) has not been well defined. Therefore, we used the 2003 United States Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample database to estimate VTE events among hospitalised medical patients. We then modeled the potential reduction in VTE with universal utilisation of appropriate pharmacological thromboprophylaxis. We calculated that 8,077,919 acutely ill hospitalised medical patients were at risk for VTE. Heart failure, respiratory failure, pneumonia, and cancer were the most common medical diagnoses. We estimated that 196,134 VTE-related events occurred in 2003, afflicting two out of every 100 acutely ill hospitalised medical patients. These VTE-related events were comprised of 122,235 symptomatic deep venous thromboses, 32,654 symptomatic episodes of pulmonary embolism, and 41,245 deaths due to VTE. In our model, rates of pharmacological thromboprophylaxis prescription were low for various acute medical illnesses, ranging from 15.3% to 49.2%. However, with universal thromboprophylaxis, 114,174 VTE-related events would have been prevented. In conclusion, acutely ill medical patients represent a large population vulnerable to the development of VTE during hospitalisation. The number of VTE-related events would be halved with universal thromboprophylaxis. Further efforts focused on improving VTE prevention strategies in hospitalised medical patients are warranted.

Entities:  

Mesh:

Year:  2009        PMID: 19718471      PMCID: PMC3062437          DOI: 10.1160/TH09-03-0150

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  37 in total

1.  A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery.

Authors:  G Oster; R L Tuden; G A Colditz
Journal:  JAMA       Date:  1987-01-09       Impact factor: 56.272

2.  A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction.

Authors:  C Warlow; G Terry; A C Kenmure; A G Beattie; D Ogston; A S Douglas
Journal:  Lancet       Date:  1973-10-27       Impact factor: 79.321

3.  Low-dose heparin after myocardial infarction.

Authors:  A J Handley
Journal:  Lancet       Date:  1972-09-23       Impact factor: 79.321

4.  Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach.

Authors:  P Doubilet; C B Begg; M C Weinstein; P Braun; B J McNeil
Journal:  Med Decis Making       Date:  1985       Impact factor: 2.583

5.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.

Authors:  M M Samama; A T Cohen; J Y Darmon; L Desjardins; A Eldor; C Janbon; A Leizorovicz; H Nguyen; C G Olsson; A G Turpie; N Weisslinger
Journal:  N Engl J Med       Date:  1999-09-09       Impact factor: 91.245

6.  Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study.

Authors:  Raza Alikhan; Alexander T Cohen; Sophie Combe; Meyer M Samama; Louis Desjardins; Amiram Eldor; Charles Janbon; Alain Leizorovicz; Carl-Gustav Olsson; Alexander G G Turpie
Journal:  Arch Intern Med       Date:  2004-05-10

7.  Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study.

Authors:  Raza Alikhan; Alexander T Cohen; Sophie Combe; Meyer M Samama; Louis Desjardins; Amiram Eldor; Charles Janbon; Alain Leizorovicz; Carl-Gustav Olsson; Alexander G G Turpie
Journal:  Blood Coagul Fibrinolysis       Date:  2003-06       Impact factor: 1.276

8.  Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.

Authors:  Alain Leizorovicz; Alexander T Cohen; Alexander G G Turpie; Carl-Gustav Olsson; Paul T Vaitkus; Samuel Z Goldhaber
Journal:  Circulation       Date:  2004-08-02       Impact factor: 29.690

9.  Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis.

Authors:  Susan R Kahn; Ian Shrier; Jim A Julian; Thierry Ducruet; Louise Arsenault; Marie-José Miron; Andre Roussin; Sylvie Desmarais; France Joyal; Jeannine Kassis; Susan Solymoss; Louis Desjardins; Donna L Lamping; Mira Johri; Jeffrey S Ginsberg
Journal:  Ann Intern Med       Date:  2008-11-18       Impact factor: 25.391

10.  Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients.

Authors:  Gregory Piazza; Erin J Rosenbaum; William Pendergast; Joseph O Jacobson; Robert C Pendleton; Gordon D McLaren; C Gregory Elliott; Scott M Stevens; William F Patton; Ousama Dabbagh; Marilyn D Paterno; Elaine Catapane; Zhongzhen Li; Samuel Z Goldhaber
Journal:  Circulation       Date:  2009-04-13       Impact factor: 29.690

View more
  13 in total

1.  [Alternative sonographic diagnoses in patients with clinical suspicion of deep vein thrombosis].

Authors:  Bettina-Maria Taute; Hannes Melnyk; Hubert Podhaisky
Journal:  Med Klin (Munich)       Date:  2010-09-28

2.  Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study.

Authors:  Hisham Badreldin
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

3.  Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis.

Authors:  Claudio Cimminiello; Paolo Prandoni; Giancarlo Agnelli; Giovanni Di Minno; Hernan Polo Friz; Francesco Scaglione; Patrizia Boracchi; Giuseppe Marano; Job Harenberg
Journal:  Intern Emerg Med       Date:  2017-07-29       Impact factor: 3.397

Review 4.  Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.

Authors:  Ida Ehlers Albertsen; Torben Bjerregaard Larsen; Lars Hvilsted Rasmussen; Thure Filskov Overvad; Gregory Y H Lip
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

5.  Evaluation of anticoagulation selection for acute venous thromboembolism.

Authors:  Hisham Badreldin; Hunter Nichols; Jessica Rimsans; Danielle Carter
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

Review 6.  Prevention of venous thromboembolism in acutely ill medical patients after the results of recent trials with the new oral anticoagulants.

Authors:  Davide Imberti; Raffaella Benedetti; Walter Ageno
Journal:  Intern Emerg Med       Date:  2013-07-16       Impact factor: 3.397

7.  Socioeconomic factors and concomitant diseases are related to the risk for venous thromboembolism during long time follow-up.

Authors:  Nazim Isma; Juan Merlo; Henrik Ohlsson; Peter J Svensson; Bengt Lindblad; Anders Gottsäter
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

Review 8.  Physician alerts to prevent venous thromboembolism.

Authors:  Gregory Piazza; Samuel Z Goldhaber
Journal:  J Thromb Thrombolysis       Date:  2010-07       Impact factor: 2.300

9.  Restenosis and therapy.

Authors:  Laszlo Denes; Laszlo Entz; Veronika Jancsik
Journal:  Int J Vasc Med       Date:  2012-02-23

10.  Incidences and variations of hospital acquired venous thromboembolism in Australian hospitals: a population-based study.

Authors:  Hassan Assareh; Jack Chen; Lixin Ou; Ken Hillman; Arthas Flabouris
Journal:  BMC Health Serv Res       Date:  2016-09-22       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.